ISPOR Europe 2018
10-14 November 2018
Barcelona, Spain
Conference Presentations
Presentation, posters, and abstracts from past conferences—searchable by disease/disorder, topic, conference, author, keyword—can be found at the ISPOR Presentations Database.
Search Presentations Database
PLENARY SESSIONS
See descriptions of the conference plenaries here.
-
PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States
-
PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States
-
PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States
-
PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States
-
PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States
-
PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States
-
PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States
-
PL3 : Budget Impact and Expenditure Caps: Potential or Pitfall?
-
PL3 : Budget Impact and Expenditure Caps: Potential or Pitfall?
-
PL3 : Budget Impact and Expenditure Caps: Potential or Pitfall?
-
PL3 : Budget Impact and Expenditure Caps: Potential or Pitfall?
Educational Symposiums
-
S1 : HOW SHOULD WE MEASURE QUALITY OF LIFE IMPACT IN RARE DISEASE?: RECENT LEARNINGS IN SPINAL MUSCULAR ATROPHY - Sponsored by Biogen
Presentation
Martina Garau
MSc, Principal Economist, Office of Health Economics, London, United Kingdom
Josie Godfrey
Director, JG Zebra Consulting,
Andrew Lloyd
Director, Acaster Lloyd Consulting Ltd.,
Julio Lopez Bastida
Professor, Universidad Castilla-La Mancha,
-
S2 : AUTOMATION IN PUBLIC HEALTH DECISION MAKING: HOW FAR CAN IT GO, HOW FAR SHOULD IT GO? - Sponsored by Analytica Laser, a Certara Company
Presentation
Hans-Peter Dauben
MD, PhD, Secretary General at EuroScan International Network e.V., & Senior Scientist at Rheinische Fachhochschule Köln gGmbH, Cologne, Germany
-
S2 : AUTOMATION IN PUBLIC HEALTH DECISION MAKING: HOW FAR CAN IT GO, HOW FAR SHOULD IT GO? - Sponsored by Analytica Laser, a Certara Company
Presentation
Jim Nasr
MBA, BSc, VP, Technology & Innovation, Synchrogenix, a Certara Company, Wilmington, USA
-
S2 : AUTOMATION IN PUBLIC HEALTH DECISION MAKING: HOW FAR CAN IT GO, HOW FAR SHOULD IT GO? - Sponsored by Analytica Laser, a Certara Company
Presentation
Sandy Allerheiligen
PhD, SVP, Strategic Consulting, Health Economics and Education, Certara, Princeton, USA
Billy Amzal
SVP, Decision and Real-World Data Analytics, Analytica Laser,
-
S3 : INDICATION-BASED PRICING; WHO WINS, WHO LOSES, AND WHERE NEXT? - Sponsored by AstraZeneca
-
S3 : INDICATION-BASED PRICING; WHO WINS, WHO LOSES, AND WHERE NEXT? - Sponsored by AstraZeneca
Presentation
Francis Arickx
Pharmacist, Head of the Directorate Reimbursement of Medicines and Pharmaceutical Policy, National Institute for Health and Disability Insurance RIZIV INAMI, Brussels, Belgium
Paul Naish
Director, Oncology Advocacy & Government Affairs, AstraZeneca,
Greg Rossi
Vice President, Global Medicines Leader (Lynparza), AstraZeneca,
-
S4 : RAISING ORGANIZATIONAL FLUENCY IN REAL WORLD EVIDENCE THROUGH INTERACTIVE LEARNING TECHNIQUES - Sponsored by Syneos Health
Presentation
David Thompson
PhD, Senior Vice President, Syneos Health, Boston, USA
Yvonne Ash
Vice President, Syneos Health,
Claire Methven
Real World Evidence Manager, Janssen,
-
S5 : REDUCING PAYER UNCERTAINTY BY PREDICTING DISEASE OUTCOMES AND IDENTIFYING THE RIGHT PATIENT: FACT OR FANTASY? - Sponsored by Takeda Pharmaceutical Company
Presentation
Mark Ratcliffe
PhD, Chief Executive Officer, PHMR Ltd, London, United Kingdom
Peter Clark
National Clinical Lead for Chemotherapy, NHS England,
Pauline Hernandez
Patient at Inflammatory Bowel Disease,
Panos Kanavos
Associate Professor in International Health Policy, London School of Economics and Political Science,
Nicky Liebermann
Head of Medicine Community Division, Clalit Health Services,
Peter Lindgren
Research Director, The Swedish Institute for Health Economics (IHE),
-
S7 : ADVANCES IN HEOR: NEW FRONTIERS BASED ON DEVELOPMENTS IN ARTIFICIAL INTELLIGENCE - Sponsored by Analysis Group
Presentation
Eric Q. Wu
PhD, Managing Principal, Analysis Group, Inc., Boston, USA
Rajeev Ayyagari
Manager, Analysis Group, Inc.,
Jimmy Royer
Vice-President, Analysis Group, Inc.,
Robert Stewart
Professor, King’s College,
ISSUE PANEL PRESENTATIONS
-
IP1 : GLOBAL BIOPHARMACEUTICAL INNOVATION - TOO MUCH, TOO LITTLE, OR BOTH?
Presentation
Charles E. Phelps
PhD, MBA, University Professor and Provosts Emeritus, University of Rochester, Gualala, USA
-
IP1 : GLOBAL BIOPHARMACEUTICAL INNOVATION - TOO MUCH, TOO LITTLE, OR BOTH?
Presentation
Patricia M. Danzon
PhD, Celia Moh Professor Emeritus, University of Pennsylvania, Philadelphia, USA
-
IP1 : GLOBAL BIOPHARMACEUTICAL INNOVATION - TOO MUCH, TOO LITTLE, OR BOTH?
-
IP11 : THE EVOLVING EU POLICY LANDSCAPE: ARE WE ON THE RIGHT PATH TO IMPROVE CLINICAL AND ECONOMIC OUTCOMES RESEARCH OF MEDICAL DEVICES?
Presentation
Rosanna Tarricone
MSc, PhD, Associate SDA Dean, SDA Bocconi School of Management, Milan, Italy
-
IP11 : THE EVOLVING EU POLICY LANDSCAPE: ARE WE ON THE RIGHT PATH TO IMPROVE CLINICAL AND ECONOMIC OUTCOMES RESEARCH OF MEDICAL DEVICES?
Presentation
Carlo Federici
MSc, SDA Research Fellow, SDA Bocconi School of Management, MILANO, Italy
-
IP11 : THE EVOLVING EU POLICY LANDSCAPE: ARE WE ON THE RIGHT PATH TO IMPROVE CLINICAL AND ECONOMIC OUTCOMES RESEARCH OF MEDICAL DEVICES?
-
IP11 : THE EVOLVING EU POLICY LANDSCAPE: ARE WE ON THE RIGHT PATH TO IMPROVE CLINICAL AND ECONOMIC OUTCOMES RESEARCH OF MEDICAL DEVICES?
Presentation
Jean Luc Lemercier
Pharm.D, Corporate Vice President, EMEA, Canada and Latin America, Edwards Lifesciences, Irvine, USA
-
IP12 : WHAT DOES PATIENT-CENTERED CARE MEAN FOR MEDICINE IN THE WELFARE STATES OF EUROPE?
-
IP13 : DIGITAL HEALTH VS. PATIENT PRIVACY (GENERAL DATA PROTECTION REGULATION): IS THE FUTURE HERE TO STAY?
Presentation
Vladimir Zah
DPhil, Visiting Professor of Health Economics, Kozminski University, Warszawa, Poland
-
IP13 : DIGITAL HEALTH VS. PATIENT PRIVACY (GENERAL DATA PROTECTION REGULATION): IS THE FUTURE HERE TO STAY?
Presentation
Ken Redekop
PhD, Associate Professor, Erasmus University Rotterdam, Rotterdam, Netherlands
-
IP13 : DIGITAL HEALTH VS. PATIENT PRIVACY (GENERAL DATA PROTECTION REGULATION): IS THE FUTURE HERE TO STAY?
Presentation
Katarzyna Kolasa
PhD, Professor of Health Economics, Head of Department, Kozminski University, Warszawa, Poland
-
IP13 : DIGITAL HEALTH VS. PATIENT PRIVACY (GENERAL DATA PROTECTION REGULATION): IS THE FUTURE HERE TO STAY?
Presentation
Carl V. Asche
PhD, Director, University of Illinois College of Medicine at Peoria, Peoria, USA
-
IP14 : EVALUATING MEDICAL DEVICES: HOW DOES RANDOMISED CLINICAL TRIAL DATA AND REAL-WORLD DATA FIT TOGETHER?
Presentation
Isabelle Durand-Zaleski
MD, PhD, Director of the URC ECO Ile-De-France, Unité de recherche clinique en économie de la santé d’Ile-de-France, Paris, France
-
IP14 : EVALUATING MEDICAL DEVICES: HOW DOES RANDOMISED CLINICAL TRIAL DATA AND REAL-WORLD DATA FIT TOGETHER?
Presentation
Michelle Jenks
BA, MSc, Project Director, York Health Economics Consortium, York, United Kingdom
-
IP14 : EVALUATING MEDICAL DEVICES: HOW DOES RANDOMISED CLINICAL TRIAL DATA AND REAL-WORLD DATA FIT TOGETHER?
Presentation
Petra Schnell-Inderst
MPH, Dipl. Biol, Senior Scientist, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria
-
IP14 : EVALUATING MEDICAL DEVICES: HOW DOES RANDOMISED CLINICAL TRIAL DATA AND REAL-WORLD DATA FIT TOGETHER?
-
IP15 : TRANSFORMING HEALTHCARE: THE IMPACT OF PATIENT ENGAGEMENT
-
IP16 : VALUING A CURE: ARE NEW APPROACHES NEEDED?
Presentation
Mark Sculpher
PhD, Professor of Health Economics, University of York, York, United Kingdom
-
IP16 : VALUING A CURE: ARE NEW APPROACHES NEEDED?
Presentation
Sarah Garner
PhD, Co-ordinator -- Innovation, Access and Use, World Health Organization, Geneva, Switzerland
-
IP16 : VALUING A CURE: ARE NEW APPROACHES NEEDED?
Presentation
Jens Grueger
PhD, Vice President and Head of Global Pricing and Market Access, Roche, Basel, Switzerland
-
IP16 : VALUING A CURE: ARE NEW APPROACHES NEEDED?
Presentation
Steven D Pearson
MD, MSc, President, Institute for Clinical and Economic Review, Boston, USA
-
IP17 : CHALLENGES IN THE VALUE ASSESSMENT, PRICING, AND FUNDING OF TARGETED COMBINATION THERAPIES IN ONCOLOGY
-
IP18 : DRUG DISINVESTMENT – IS IT NEEDED AND HOW COULD IT WORK?
Presentation
Bettina Ryll
MD, PhD, Founder, and Researcher, Melanoma Patient Network Europe, and Uppsala University (Department EBC), Uppsala, Sweden
-
IP18 : DRUG DISINVESTMENT – IS IT NEEDED AND HOW COULD IT WORK?
Presentation
Detlev Parow
MD, MBA, Head of Pharmaceutical Department, D A K - Gesundheit, Hamburg, Germany
-
IP18 : DRUG DISINVESTMENT – IS IT NEEDED AND HOW COULD IT WORK?
-
IP18 : DRUG DISINVESTMENT – IS IT NEEDED AND HOW COULD IT WORK?
-
IP19 : STRUCTURAL IMPLEMENTATION OF PATIENT PREFERENCES IN HEALTH TECHNOLOGY ASSESSMENT: WILL WE EVER GET THERE? A QUESTION RAISED BY IMI PREFER
Presentation
David Mott
Economist, Office of Health Economics, London, UK
Dr. Marco Petschulies
Scientific Advisor, Federal Joint Committee (G-BA), Berlin, Germany
Eline van Overbeeke
PhD researcher, University of Leuven, Leuven, Belgium
-
IP2 : CAN PATIENT INVOLVEMENT IN EARLY DIALOGUES (EARLY SCIENTIFIC ADVICE) INCREASE THE VALUE OF THE ADVICE GIVEN?
-
IP20 : HOW PRIVATE HEALTH INSURANCE CAN SUPPORT THE IMPLEMENTATION OF UNIVERSAL HEALTH COVERAGE IN EMERGING ECONOMIES?
Presentation
Zoltán Kaló
PhD, Professor of Health Economics, Syreon Research Institute, Budapest, Hungary
-
IP21 : ACCESS TO HIGHLY SPECIALISED TREATMENTS FOR RARE CONDITIONS, WHAT IS THE ROLE OF REAL WORLD EVIDENCE TO ADDRESS HTA AND PAYER UNCERTAINTY?
Presentation
Lieven Annemans
PhD, MSc, Senior Full Professor of Health Economics, Ghent University, Ghent, Belgium
-
IP21 : ACCESS TO HIGHLY SPECIALISED TREATMENTS FOR RARE CONDITIONS, WHAT IS THE ROLE OF REAL WORLD EVIDENCE TO ADDRESS HTA AND PAYER UNCERTAINTY?
Presentation
Sheela Upadhyaya
MSc, Associate Director - Highly Specialised Technologies, NICE - National Institute for Health and Care Excellence, London, United Kingdom
-
IP22 : ARE SINGLE-ARM CLINICAL TRIALS SUFFICIENT TO ASSESS VALUE IN ONCOLOGY AND RARE DISEASES?
Presentation
Mondher Toumi
MD, PhD, MSc, Professor, Public Health, Aix-Marseille University, Marseille, France
-
IP22 : ARE SINGLE-ARM CLINICAL TRIALS SUFFICIENT TO ASSESS VALUE IN ONCOLOGY AND RARE DISEASES?
-
IP22 : ARE SINGLE-ARM CLINICAL TRIALS SUFFICIENT TO ASSESS VALUE IN ONCOLOGY AND RARE DISEASES?
-
IP23 : CAN WE BELIEVE THEIR BELIEFS: IS EXPERT ELICITATION (COST-) EFFECTIVE?
Presentation
Lotte Steuten
PhD, MSc, Associate Professor & Director, Fred Hutchinson Institute for Cancer Outcomes, Seattle, USA
-
IP23 : CAN WE BELIEVE THEIR BELIEFS: IS EXPERT ELICITATION (COST-) EFFECTIVE?
Presentation
Neil Hawkins
PhD, CStat, Professor of HTA, University of Glasgow, Glasgow, United Kingdom
-
IP23 : CAN WE BELIEVE THEIR BELIEFS: IS EXPERT ELICITATION (COST-) EFFECTIVE?
Presentation
Alec Morton
PhD, Professor of Management Science, University of Strathclyde, Glasgow, Scotland, United Kingdom
-
IP23 : CAN WE BELIEVE THEIR BELIEFS: IS EXPERT ELICITATION (COST-) EFFECTIVE?
-
IP24 : VALUE OF DIAGNOSTIC INFORMATION: HOW TO MOVE FROM CONCEPT TO REALITY OF EVALUATING AND MEASURING THE VALUE OF DIAGNOSTIC INFORMATION
-
IP24 : VALUE OF DIAGNOSTIC INFORMATION: HOW TO MOVE FROM CONCEPT TO REALITY OF EVALUATING AND MEASURING THE VALUE OF DIAGNOSTIC INFORMATION
Presentation
Hendrik Koffijberg
PhD, Associate Professor, University of Twente, Enchede, Netherlands
-
IP25 : Should Nutritional Products Be Evaluated and Reimbursed The Same Way Pharmaceuticals Are?
-
IP26 : WILL REGENERATIVE MEDICINES CHANGE THE WAY WE EVALUATE EVIDENCE, FUND INNOVATION, AND DETERMINE VALUE?
-
IP27 : ADDRESSING CHALLENGES TO OPEN SCIENCE: DATA SHARING, REPLICATION, AND ROBUSTNESS OF EVIDENCE FROM REAL WORLD DATA
Presentation
Anna Garcia-Altes
MSc, MPH, PhD, Researcher, Catalan Agency for Health Technology Assessment and Research, Barcelona, Spain
-
IP27 : ADDRESSING CHALLENGES TO OPEN SCIENCE: DATA SHARING, REPLICATION, AND ROBUSTNESS OF EVIDENCE FROM REAL WORLD DATA
Presentation
Shirley V. Wang
PhD, Assistant Professor of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA
-
IP27 : ADDRESSING CHALLENGES TO OPEN SCIENCE: DATA SHARING, REPLICATION, AND ROBUSTNESS OF EVIDENCE FROM REAL WORLD DATA
Presentation
Amr Makady
PharmD, PhD, Policy Advisor, The National Healthcare Institute (ZIN), Diemen, Netherlands
-
IP3 : WILL MACHINES SOON MAKE HEALTH ECONOMISTS OBSOLETE?
-
IP3 : WILL MACHINES SOON MAKE HEALTH ECONOMISTS OBSOLETE?
Presentation
Gerry Oster
PhD, Senior Economist, Policy Analysis Inc. (PAI) and Managing Co-Director, MINERVA Health Economics Network, Brookline, USA
-
IP3 : WILL MACHINES SOON MAKE HEALTH ECONOMISTS OBSOLETE?
Presentation
Michael Drummond
MCom, DPhil, Professor of Health Economics, University of York, Heslington, York, United Kingdom
-
IP5 : PROVE IT WITH PROS
-
IP6 : DO NOVEL VALUE MEASURES HAVE A PLACE IN EUROPEAN HTA?
Presentation
J. Ross Maclean
MD, PhD, Senior Vice President, Head of Medical Affairs, Precision Health Economics, Los Angeles, USA
-
IP6 : DO NOVEL VALUE MEASURES HAVE A PLACE IN EUROPEAN HTA?
-
IP6 : DO NOVEL VALUE MEASURES HAVE A PLACE IN EUROPEAN HTA?
Presentation
Mark Sculpher
PhD, Professor of Health Economics, University of York, York, United Kingdom
-
IP6 : DO NOVEL VALUE MEASURES HAVE A PLACE IN EUROPEAN HTA?
Presentation
Jens Grueger
PhD, Vice President and Head of Global Pricing and Market Access, Roche, Basel, Switzerland
-
IP7 : CHANGING PARADIGM IN THE EVALUATION OF THE VALUE OF MEDICAL DEVICES: WHAT MUST STAKEHOLDERS EXPECT IN THE NEW DECADE?
-
IP7 : CHANGING PARADIGM IN THE EVALUATION OF THE VALUE OF MEDICAL DEVICES: WHAT MUST STAKEHOLDERS EXPECT IN THE NEW DECADE?
Presentation
Oyvind Melien
Department Director, Reviews and HTA, Norwegian Institute of Public Health, Oslo, Norway
-
IP8 : HTA VALUE BASED PRICING VERSUS WHO FAIR PRICING. WHICH DELIVERS UNIVERSAL HEALTH COVERAGE?
-
IP8 : HTA VALUE BASED PRICING VERSUS WHO FAIR PRICING. WHICH DELIVERS UNIVERSAL HEALTH COVERAGE?
Presentation
Kalipso Chalkidou
MD, PhD, Director Global Health Policy, Center for Global Development, London, United Kingdom
-
IP8 : HTA VALUE BASED PRICING VERSUS WHO FAIR PRICING. WHICH DELIVERS UNIVERSAL HEALTH COVERAGE?
Presentation
Sarah Garner
PhD, Co-ordinator -- Innovation, Access and Use, World Health Organization, Geneva, Switzerland
-
IP9 : BACK TO THE FUTURE: SHOULD WE LIVE IN A POST-QALY WORLD?
Presentation
John Spoors
BA (Hons), DipHE, Associate Director, RJW & Partners, London, United Kingdom
WORKSHOP PRESENTATIONS
-
W1 : ROADBLOCKS AND RESOLUTIONS: DEVELOPMENT OF PRO INSTRUMENTS FOR MULTINATIONAL TRIALS (Advanced Workshop)
-
W10 : UNDERSTANDING AND ADDRESSING POTENTIAL BIAS IN PATIENT-REPORTED OUTCOMES FROM CLINICAL TRIALS (Advanced Workshop)
-
W10 : UNDERSTANDING AND ADDRESSING POTENTIAL BIAS IN PATIENT-REPORTED OUTCOMES FROM CLINICAL TRIALS (Advanced Workshop)
Presentation
Donald E Stull
PhD, Head, Data Analytics and Design Strategy, RTI Health Solutions, Durham, USA
-
W10 : UNDERSTANDING AND ADDRESSING POTENTIAL BIAS IN PATIENT-REPORTED OUTCOMES FROM CLINICAL TRIALS (Advanced Workshop)
-
W11 : CHALLENGES AND LESSONS LEARNED FROM ELECTRONIC RECRUITMENT AND VALIDATION OF PATIENTS FOR OUTCOME RESEARCH STUDIES IN RARE DISEASES
-
W12 : ARE MISSING DATA PROPERLY ACCOUNTED FOR IN HEALTH ECONOMICS AND OUTCOMES RESEARCH? (Advanced Workshop)
Presentation
Gianluca Baio
PhD, Reader in Statistics & Health Economics, University College London, London, United Kingdom
-
W13 : ECONOMIC EVALUATION TRANSFERABILITY: A COMPARATIVE EXAMINATION OF ASSESSING MEDICAL DEVICES ACROSS THE EU IN THE CONTEXT OF NEW HTA PROPOSAL OF THE EUROPEAN COMMISSION
-
W14 : PATIENT-FOCUSED DRUG DEVELOPMENT AND PATIENT-CENTERED CLINICAL CARE: WORKING TOGETHER.
Presentation
Robert McBurney
PhD, Co-Principal Investigator, iConquerMS™ - the MS Patient-Powered Research Network, Accelerated Cure Project for MS, Chestnut Hill, USA
-
W15 : SURVIVAL EXTRAPOLATION: HOW TO DRAW THE LINES BEYOND THE OBSERVED DATA, IF YOU MUST
-
W16 : WHAT IS GOOD FOR THE ENVIRONMENT IS GOOD FOR HEALTHCARE – HOW TO CONSIDER GREEN SUSTAINABILITY IN VALUE ASSESSMENTS AND PURCHASING DECISIONS
Presentation
Mark Sculpher
PhD, Professor of Health Economics, University of York, York, United Kingdom
-
W16 : WHAT IS GOOD FOR THE ENVIRONMENT IS GOOD FOR HEALTHCARE – HOW TO CONSIDER GREEN SUSTAINABILITY IN VALUE ASSESSMENTS AND PURCHASING DECISIONS
Presentation
Mike Baldwin
MBA, BA, Market Access Director, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
-
W16 : WHAT IS GOOD FOR THE ENVIRONMENT IS GOOD FOR HEALTHCARE – HOW TO CONSIDER GREEN SUSTAINABILITY IN VALUE ASSESSMENTS AND PURCHASING DECISIONS
-
W16 : WHAT IS GOOD FOR THE ENVIRONMENT IS GOOD FOR HEALTHCARE – HOW TO CONSIDER GREEN SUSTAINABILITY IN VALUE ASSESSMENTS AND PURCHASING DECISIONS
Presentation
Carolin Miltenburger
MSc, PhD, Owner and Principal, Miltenburger Consulting, Berlin, Germany
-
W17 : ESTIMATING COMPARATIVE EFFECTIVENESS IN THE PRESENCE OF TREATMENT SWITCHING AND DELAYED INITIATION (AND OTHER REAL-WORLD DATA CHALLENGES!)
Presentation
Nicholas Latimer
MSc, PhD, Reader in Health Economics, University of Sheffield, Sheffield, United Kingdom
-
W17 : ESTIMATING COMPARATIVE EFFECTIVENESS IN THE PRESENCE OF TREATMENT SWITCHING AND DELAYED INITIATION (AND OTHER REAL-WORLD DATA CHALLENGES!)
-
W17 : ESTIMATING COMPARATIVE EFFECTIVENESS IN THE PRESENCE OF TREATMENT SWITCHING AND DELAYED INITIATION (AND OTHER REAL-WORLD DATA CHALLENGES!)
Presentation
Melvin (Skip) Olson
PhD, Global Head RWD Strategy and Innovation, Novartis Pharma AG, Basel, Switzerland
-
W17 : ESTIMATING COMPARATIVE EFFECTIVENESS IN THE PRESENCE OF TREATMENT SWITCHING AND DELAYED INITIATION (AND OTHER REAL-WORLD DATA CHALLENGES!)
Presentation
Daniel Rosenberg
PhD, Head Epidemiology & Observational Studies, Actelion Pharmaceticals Ltd, Allschwil, Switzerland
-
W18 : CONFOUNDING BY INDICATION - CURRENT PRACTICES AND FUTURE APPLICATIONS
Presentation
Xavier Pouwels
MSc, Junior researcher in Health Economics/ Phd candidate, Maastricht University Medical Centre+, Maastricht, Netherlands
-
W18 : CONFOUNDING BY INDICATION - CURRENT PRACTICES AND FUTURE APPLICATIONS
Presentation
Wietske Kievit
PhD, Post-doctoral researcher, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
-
W18 : CONFOUNDING BY INDICATION - CURRENT PRACTICES AND FUTURE APPLICATIONS
Presentation
Richard Grieve
PhD, Professor of Health Economics Methodology, London School of Hygiene and Tropical Medicine, London, United Kingdom
-
W18 : CONFOUNDING BY INDICATION - CURRENT PRACTICES AND FUTURE APPLICATIONS
Presentation
Manuela Joore
PhD, Professor in Health Technology Assessment and Decision-Making, Maastricht University Medical Centre, Maastricht, Netherlands
-
W19 : R YOU SERIOUSLY STILL USING EXCEL? THE MANY ADVANTAGES OF OPEN SOURCE DECISION MODELLING IN EFFICIENT PROGRAMMING LANGUAGES
Presentation
Gianluca Baio
PhD, Reader in Statistics & Health Economics, University College London, London, United Kingdom
-
W19 : R YOU SERIOUSLY STILL USING EXCEL? THE MANY ADVANTAGES OF OPEN SOURCE DECISION MODELLING IN EFFICIENT PROGRAMMING LANGUAGES
Presentation
Jeroen P Jansen
PhD, Lead Scientific Advisor - Open Source Value Project, Innovation and Value Initiative, Los Angeles, USA
-
W19 : R YOU SERIOUSLY STILL USING EXCEL? THE MANY ADVANTAGES OF OPEN SOURCE DECISION MODELLING IN EFFICIENT PROGRAMMING LANGUAGES
Presentation
Devin Incerti
PhD, Lead Economist - Open Source Value Project, Innovation and Value Initiative, Los Angeles, USA
-
W19 : R YOU SERIOUSLY STILL USING EXCEL? THE MANY ADVANTAGES OF OPEN SOURCE DECISION MODELLING IN EFFICIENT PROGRAMMING LANGUAGES
Presentation
Howard Thom
BA, MSc, PhD, Research Fellow in Statistical Modelling, University of Bristol, Bristol, United Kingdom
-
W2 : CHALLENGES IN THE USE OF REAL-WORLD EVIDENCE FOR PHARMACOECONOMIC MODELLING
-
W20 : WHEN DO WE HAVE ENOUGH EVIDENCE TO ACCEPT MIGRATION OF PATIENT-REPORTED OUTCOME MEASURES (PROMS) FROM PAPER TO SCREEN-BASED FORMATS WITHOUT ADDITIONAL TESTING?
Presentation
Bill Byrom
B.Sc., Ph.D., Vice President of Product Strategy and Innovation, CRF Health, London, United Kingdom
-
W21 : INDIRECT TREATMENT COMPARISONS: AN INTERACTIVE WORKSHOP ON CHOOSING THE RIGHT TOOL FOR THE AVAILABLE DATA
Presentation
Necdet Gunsoy
MPH PhD, Manager of Analytics and Innovation for Value Evidence and Outcomes, GlaxoSmithKline (GSK), Uxbridge, United Kingdom
-
W22 : POLICY MEASURES TO MAXIMISE PATIENT ACCESS AFTER THE INTRODUCTION OF BIOSIMILAR MEDICINES IN THE OFF-PATENT BIOLOGICAL MARKET
-
W22 : POLICY MEASURES TO MAXIMISE PATIENT ACCESS AFTER THE INTRODUCTION OF BIOSIMILAR MEDICINES IN THE OFF-PATENT BIOLOGICAL MARKET
Presentation
Andras Inotai
PharmD, PhD, DrHabil, Principal Researcher; Assistant Professor, 1) Syreon Research Institute 2) Eötvös Loránd University (ELTE), Budapest, Hungary
-
W3 : ADJUSTING FOR POSTRANDOMIZATION CONFOUNDING AND SWITCHING IN PHASE III AND PRAGMATIC TRIALS TO GET THE ESTIMANDS RIGHT: NEEDS, METHODS, SUB-OPTIMAL USE, AND ACCEPTANCE IN HTA (Advanced Workshop)
Presentation
Felicitas Kuhne
MSc, Junior Scientist, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i. T., Austria
-
W3 : ADJUSTING FOR POSTRANDOMIZATION CONFOUNDING AND SWITCHING IN PHASE III AND PRAGMATIC TRIALS TO GET THE ESTIMANDS RIGHT: NEEDS, METHODS, SUB-OPTIMAL USE, AND ACCEPTANCE IN HTA (Advanced Workshop)
Presentation
Uwe Siebert
Prof, MPH, MSc, ScD, MD, Professor, UMIT - University for Health Sciences, Medical Informatics and Technology / Harvard T.H. Chan School of Public Health / Harvard Medical School, Boston, MA, USA, Hall i.T., Austria
-
W3 : ADJUSTING FOR POSTRANDOMIZATION CONFOUNDING AND SWITCHING IN PHASE III AND PRAGMATIC TRIALS TO GET THE ESTIMANDS RIGHT: NEEDS, METHODS, SUB-OPTIMAL USE, AND ACCEPTANCE IN HTA (Advanced Workshop)
Presentation
Nicholas Latimer
PhD, Reader in Health Economics, ScHARR - University of Sheffield, Sheffield, United Kingdom
-
W3 : ADJUSTING FOR POSTRANDOMIZATION CONFOUNDING AND SWITCHING IN PHASE III AND PRAGMATIC TRIALS TO GET THE ESTIMANDS RIGHT: NEEDS, METHODS, SUB-OPTIMAL USE, AND ACCEPTANCE IN HTA (Advanced Workshop)
Presentation
Amanda Adler
MD, PhD, FRCP, Chair, Addenbrooks’s Hospital/National Institute for Health and Care Excellence, Cambridge, United Kingdom
-
W4 : TOWARDS PERSONALIZATION: HOW CAN ADVANCED QUANTITATIVE METHODS HELP REGULATORS, REIMBURSEMENT AGENCIES AND CLINICIANS MAKE BETTER DECISIONS FOR INDIVIDUAL PATIENTS? (Advanced Workshop)
Presentation
Richard Grieve
PhD, Professor, London School of Hygiene and Tropical Medicine, London, United Kingdom
-
W4 : TOWARDS PERSONALIZATION: HOW CAN ADVANCED QUANTITATIVE METHODS HELP REGULATORS, REIMBURSEMENT AGENCIES AND CLINICIANS MAKE BETTER DECISIONS FOR INDIVIDUAL PATIENTS? (Advanced Workshop)
-
W4 : TOWARDS PERSONALIZATION: HOW CAN ADVANCED QUANTITATIVE METHODS HELP REGULATORS, REIMBURSEMENT AGENCIES AND CLINICIANS MAKE BETTER DECISIONS FOR INDIVIDUAL PATIENTS? (Advanced Workshop)
Presentation
Neil Hawkins
PhD, CStat, Professor of HTA, University of Glasgow, Glasgow, United Kingdom
-
W4 : TOWARDS PERSONALIZATION: HOW CAN ADVANCED QUANTITATIVE METHODS HELP REGULATORS, REIMBURSEMENT AGENCIES AND CLINICIANS MAKE BETTER DECISIONS FOR INDIVIDUAL PATIENTS? (Advanced Workshop)
Presentation
Anirban Basu
PhD, Stergachis Family Endowed Professor & Director, University of Washington, Seattle, USA
-
W5 : APPLICATION OF GAMIFICATION IN HEALTHCARE AND OUTCOMES MEASUREMENT: IMPROVING TREATMENT COMPLIANCE AND RESEARCH ENGAGEMENT
-
W6 : ECONOMIC MODEL CHOICE, VALIDATION, AND SHARING: PRAGMATIC ROADMAPS FOR PHARMACOECONOMIC PRACTICE (Advanced Workshop)
-
W6 : ECONOMIC MODEL CHOICE, VALIDATION, AND SHARING: PRAGMATIC ROADMAPS FOR PHARMACOECONOMIC PRACTICE (Advanced Workshop)
Presentation
Zoltan Kalo
PhD, Professor of Health economics, Eötvös Loránd University, Budapest, Hungary
-
W7 : Preference Research in HTA Agencies Europe
-
W8 : NOVEL APPROACHES TO COMMON CHALLENGES IN MODELLING OF SURVIVAL OUTCOMES FOR COST-EFFECTIVENESS ANALYSES IN ONCOLOGY (Advanced Workshop)
Presentation
Matthew Dyer
MSc, Health Economics and Payer Analytics Director, AstraZeneca, Cambridge, United Kingdom
-
W8 : NOVEL APPROACHES TO COMMON CHALLENGES IN MODELLING OF SURVIVAL OUTCOMES FOR COST-EFFECTIVENESS ANALYSES IN ONCOLOGY (Advanced Workshop)
Presentation
Richard Birnie
PhD, Principal Statistician, BresMed Health Solutions Ltd, Sheffield, United Kingdom
-
W9 : HOW TO COMMUNICATE COST-EFFECTIVENESS ANALYSIS TO A LAY AUDIENCE?
ISPOR FORUMS
-
F1 : VALUE OF INFORMATION (VOI) ANALYSIS FOR RESEARCH DECISIONS EMERGING GOOD PRACTICES TASK FORCE: FINAL RECOMMENDATIONS
Presentation
Elisabeth Fenwick
PhD, Senior Director, MMA, Pharmerit International, Wallingford, Oxfordshire, United Kingdom
-
F10 : PRIORITY SETTING - CRITERIA AND PROCESS OF RARE DISEASES MANAGEMENT IN CEE COUNTRIES
Presentation
Rasim Jusufović
MD, PhD, Assistant Professor, Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina
-
F10 : PRIORITY SETTING - CRITERIA AND PROCESS OF RARE DISEASES MANAGEMENT IN CEE COUNTRIES
Presentation
Dragana Atanasijevic
MD, MPH, MSc, President, Institute of Public Health of Serbia, Belgrade, Serbia
-
F10 : PRIORITY SETTING - CRITERIA AND PROCESS OF RARE DISEASES MANAGEMENT IN CEE COUNTRIES
Presentation
Ljubica Suturkova
PharmD,PhD, President, Republic of Macedonia Institute of Pharmaceutical Chemistry, Skopje, Macedonia
-
F11 : THE ISPOR HEOR COMPETENCIES FRAMEWORK™: GUIDING PROFESSIONAL DEVELOPMENT FOR THE FIELD OF HEOR
-
F12 : VALUE ASSESSMENT FRAMEWORK IN EMERGING MARKETS – EXPERIENCE FROM COUNTRIES IN THE MIDDLE EAST
Presentation
Gihan Hamdy El-sisi
MSc, PhD, Head of Pharmacoeconomic Unit, Heliopolis University, Cairo, Egypt
-
F12 : VALUE ASSESSMENT FRAMEWORK IN EMERGING MARKETS – EXPERIENCE FROM COUNTRIES IN THE MIDDLE EAST
-
F12 : VALUE ASSESSMENT FRAMEWORK IN EMERGING MARKETS – EXPERIENCE FROM COUNTRIES IN THE MIDDLE EAST
Presentation
Kasem Akhras
PharmD, Senior Director, The University of Illinois at Chicago, Dubai, United Arab Emirates
-
F2 : TOWARDS A VALUE FRAMEWORK FOR PRECISION MEDICINE: RECOMMENDATIONS FROM THE ISPOR PRECISION MEDICINE SPECIAL INTEREST GROUP
-
F3 : MARKET ACCESS IN CENTRAL AND EASTERN EUROPE: WHAT ARE THE DRIVERS AND CHALLENGES?
Presentation
Olha Zaliska
PhD, DSci, Professor, Head of the Department of Management and Economy of Pharmacy, Drug Technology and Pharmacoeconomics, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
-
F3 : MARKET ACCESS IN CENTRAL AND EASTERN EUROPE: WHAT ARE THE DRIVERS AND CHALLENGES?
-
F3 : MARKET ACCESS IN CENTRAL AND EASTERN EUROPE: WHAT ARE THE DRIVERS AND CHALLENGES?
-
F3 : MARKET ACCESS IN CENTRAL AND EASTERN EUROPE: WHAT ARE THE DRIVERS AND CHALLENGES?
Presentation
Vladimir Zah
PhD, Visiting Professor, Kozminski University, Warsaw Poland and Health Economist, CEO, ZRx Outcomes Research Inc., Serbia, Belgrade, Serbia
-
F3 : MARKET ACCESS IN CENTRAL AND EASTERN EUROPE: WHAT ARE THE DRIVERS AND CHALLENGES?
-
F4 : TRIANGULATING DEVELOPERS, REGULATORS AND PAYERS TO REAP REWARDS AND ADDRESS CHALLENGES WITH CURATIVE THERAPIES
-
F4 : TRIANGULATING DEVELOPERS, REGULATORS AND PAYERS TO REAP REWARDS AND ADDRESS CHALLENGES WITH CURATIVE THERAPIES
-
F5 : DOES MCDA LEAD TO BETTER PATIENT ACCESS IN AFRICA ?
Presentation
Mahmoud Diaa Elmahdawy
PharmD, President, ISPOR Egypt Chapter, Director, Market Access and Health Economics, Novartis, Cairo, Egypt
-
F5 : DOES MCDA LEAD TO BETTER PATIENT ACCESS IN AFRICA ?
Presentation
Redouane Soualmi
PharmD, MSc, Pricing & Market Access Manager, Boehringer Ingelheim, Algiers, Algeria
-
F5 : DOES MCDA LEAD TO BETTER PATIENT ACCESS IN AFRICA ?
Presentation
Tienie Stander
MBChB, MBA, President, ISPOR South Africa Chapter & Chief Executive Officer, TCD Research FZ-LLC, Dubai, United Arab Emirates
-
F5 : DOES MCDA LEAD TO BETTER PATIENT ACCESS IN AFRICA ?
Presentation
Daniel Asfaw Erku
BPharm, Dip Ed, PhD(c), President, ISPOR Ethiopia Chapter, University of Gondar, Gondar, Ethiopia
-
F6 : CHALLENGES IN MEDICINES FUNDING FOR RARE DISEASES
Presentation
Carme Pinyol
MD, PhD, MSc, Head of Pricing and Market Access, Southern Europe, Pierre Fabre, Barcelona, Spain
-
F6 : CHALLENGES IN MEDICINES FUNDING FOR RARE DISEASES
-
F6 : CHALLENGES IN MEDICINES FUNDING FOR RARE DISEASES
-
F6 : CHALLENGES IN MEDICINES FUNDING FOR RARE DISEASES
-
F7 : HEALTH STATE UTILITY (HSU) GOOD PRACTICES TASK FORCE RECOMMENDATIONS FOR IDENTIFICATION AND USE OF HSU DATA IN COST-EFFECTIVENESS IN DECISION MODELLING
-
F8 : WHAT CAN HEALTH ECONOMICS LEARN FROM OPERATIONS RESEARCH?
Presentation
Praveen Thokala
MASc, PhD, Research Fellow, The University of Sheffield, SHEFFIELD, United Kingdom
-
F9 : DIAGNOSTICS EVIDENTIARY DINOSAUR EVOLUTION: CONVENTIONAL HEALTH ECONOMICS AND MARKET ACCESS APPROACHES VS. ADVANCED ANALYTICS AS THE NEW NORM?
